ClinicalTrials.gg
Not yet recruitingNCT07119866Updated Aug 13, 2025

The Role of Oxygen Reserve Index (ORi) in Apneic Ventilation

An observational study in Oxygen Reserve Index, Apnea and Ventilation, sponsored by Ankara City Hospital Bilkent. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by Ankara City Hospital Bilkent · Observational

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Background: The Oxygen Reserve Index (ORI) is a non-invasive parameter utilizing multi-wavelength pulse co-oximetry. ORI can provide early warnings of deteriorating oxygenation before changes are reflected in SpO₂ levels. This study aimed to investigate the feasibility of non-ventilated intubation in patients undergoing cholecystectomy as a means to achieve safe intubation without nasogastric tube placement, with reduced trauma and cost, and improved time efficiency.

Read the detailed description

Obesity is a complex and chronic disease that significantly impacts respiratory physiology. It leads to increased work of breathing and reduced compliance of the chest wall. In morbidly obese individuals, there is a marked reduction in total lung capacity, vital capacity, forced expiratory volume in one second (FEV1), and forced vital capacity (FVC). Additionally, due to their elevated metabolic demands, these patients exhibit higher oxygen consumption rates.

The Oxygen Reserve Index (ORi) (Masimo Corp., Irvine, CA, USA) is an advanced, continuous, and non-invasive parameter that provides a relative indication of arterial partial pressure of oxygen (PaO₂).

ORI monitoring can be particularly beneficial in patients at risk for inadequate preoxygenation, those with difficult mask ventilation, hypoxemic patients with aspiration risk, rapid sequence induction scenarios, obese individuals, ICU intubations, and invasive ventilation cases. It has also been shown to provide early warnings of desaturation in select patient groups, contributing to improved patient safety.

02

Conditions studied

  • Oxygen Reserve Index
  • Apnea
  • Ventilation
  • Body Mass Index

Browse trials for

03

In context

Apnea

282 studies on the registry are indexed under Apnea; 54 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 78 observational studies indexed under Apnea.

Browse Apnea studies →

Lead sponsor

Ankara City Hospital Bilkent is the lead sponsor of 443 studies on the registry; 111 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

60 patients between the ages of 18-60 years, ASA 1-2, scheduled for elective laparoscopic cholecystectomy under general anesthesia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-60 years
  • ASA 1-2
  • Mallampati score \<2
  • Scheduled for elective laparoscopic cholecystectomy under general anesthesia

Exclusion criteria

Exclusion Criteria:

  • \<18 and >60 years
  • ASA 3-4
  • Initial ORI value below 0.24
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • ORI>0.24

    Patients, aged between 18 and 60 years, classified as ASA physical status I-II,and with a Mallampati score \<2, were enrolled.On the day of surgery, following identity verification and confirmation of the surgical site, patients were positioned on a warmed operating table.Standard monitoring was applied, including ECG, SBP and DBP, SpO₂, and the ORI.Preoxygenation was achieved by administering 100% oxygen via 8 deep breaths over 60 seconds.When the ORI value reached 0.4, intravenous anesthesia induction was initiated using propofol 2 mg/kg, fentanyl 2 mcg/kg, and rocuronium 0.6mg/kg.During muscle relaxation, patients were not ventilated via mask.The ORI value at the time of induction and at the 2nd minute post-induction was recorded.If the ORI dropped below 0.24 before the 2-minute mark, mask ventilation was initiated, and the time of intervention was noted.Endotracheal intubation was then performed using a standard,atraumatic technique after achieving adequate muscle relaxation.

    Other: OXYGEN RESERVE INDEX

  • ORI<0.24

    Patients, aged between 18 and 60 years, classified as ASA physical status I-II,and with a Mallampati score \<2, were enrolled.On the day of surgery, following identity verification and confirmation of the surgical site, patients were positioned on a warmed operating table.Standard monitoring was applied, including ECG, SBP and DBP, SpO₂, and the ORI.Preoxygenation was achieved by administering 100% oxygen via 8 deep breaths over 60 seconds.When the ORI value reached 0.4, intravenous anesthesia induction was initiated using propofol 2 mg/kg, fentanyl 2 mcg/kg, and rocuronium 0.6mg/kg.During muscle relaxation, patients were not ventilated via mask.The ORI value at the time of induction and at the 2nd minute post-induction was recorded.If the ORI dropped below 0.24 before the 2-minute mark, mask ventilation was initiated, and the time of intervention was noted.Endotracheal intubation was then performed using a standard,atraumatic technique after achieving adequate muscle relaxation.

    Other: OXYGEN RESERVE INDEX

Interventions

  • OtherOXYGEN RESERVE INDEX

    Noted for each patient.

06

What researchers measure

Primary outcomes

  1. TIME FOR ORI TO FALL BELOW 0.24

    TIME THE PATIENT STARTED TO WEAR A MASKS.

    Time frame: WITHIN 10 MINUTES BEFORE INTUBATION

Secondary outcomes

  1. INITIAL ORI VALUE

    Noted for each patient.

    Time frame: WITHIN 10 MINUTES BEFORE INTUBATION

  2. ORI VALUE AT 2 MINUTES

    Noted for each patient.

    Time frame: WITHIN 10 MINUTES BEFORE INTUBATION

  3. AGE

    Noted for each patient.

    Time frame: WITHIN 10 MINUTES BEFORE INTUBATION

  4. American Society of Anesthesiologists (ASA) Score

    Noted for each patient.

    Time frame: WITHIN 10 MINUTES BEFORE INTUBATION

  5. SEX

    Noted for each patient.

    Time frame: WITHIN 10 MINUTES BEFORE INTUBATION

  6. BMI

    Noted for each patient.

    Time frame: WITHIN 10 MINUTES BEFORE INTUBATION

  7. PRESENCE OF A NASOGASTRIC TUBE

    Noted for each patient.

    Time frame: 10 MINUTES BEFORE EXTUBATION

  8. Surgeon satisfaction

    Noted for each patient. Surgeon satisfaction according to ng usage status.

    Time frame: 10 MINUTES BEFORE EXTUBATION

  9. PRESENCE OF LARYNGOSPASM

    Noted for each patient.

    Time frame: 10 MINUTES BEFORE EXTUBATION

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Aug 2025, 0 months later.

Of 35 observational studies under Apnea, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 38. This study's planned 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Aug 13, 2025
StartEst.
Aug 7, 2025
Primary completionEst.
Aug 21, 2025
CompletionEst.
Aug 30, 2025
Last update
Aug 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07119866
Responsible party
Ayça Özcan (Prof., Ankara City Hospital Bilkent) — Principal investigator
First posted
Aug 13, 2025
Start date
Aug 7, 2025 (estimated)
Primary completion
Aug 21, 2025 (estimated)
Completion
Aug 30, 2025 (estimated)
Last update
Aug 13, 2025

Study contacts

Ayşegül Özel Erdem
Contact
aysegulozell@gmail.com
05549777289
Ayça Özcan
Contact
draycaozcan@gmail.com
05057154125

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion